Delfia prenatal screening

revvity

Prenatal screening solutions from the global leader in maternal fetal health

Full support for first trimester screening

In most countries, national recommendations guide and support the development of prenatal screening programs. While these recommendations often focus on general policies and goals, they can also include detailed recommendations on screening models and program setup.

Revvity's prenatal screening assays are clinically validated and support all modern prenatal screening strategies in the first and second trimesters and contingent testing with NIPT. Together with LifeCycle™ Prenatal Screening software, Revvity's high quality assays help you to achieve high performance in your screening program.

Timing matters

Today prenatal testing for trisomies such as Down syndrome should be carried out as early as possible – preferably in the first trimester of pregnancy. The advantage of early testing is that it offers more time for counselling, consideration and action if the risk of anomaly is found to be high. In prenatal testing, the longer you wait, the fewer options you have.

Revvity has a complete panel of first trimester analytes and fully supports the move toward first trimester prenatal screening.

Better 1T screening for aneuploidy

Routine screening for Down syndrome in the first trimester of pregnancy using the Combined test (free hCGß, PAPP-A and ultrasound nuchal translucency measurement, NT) is now the standard of prenatal care in many countries.

Yet current research shows that including maternal serum placental growth factor (PlGF) and alpha fetoprotein (AFP) in a first trimester aneuploidy screening program improves detection rates and reduces the need for invasive testing.[1-5]

> **"The performance of First Trimester Screening can be enhanced by adding PlGF and AFP. Even without nuchal translucency, the test would perform well."**
>
> Huang et al 2015

Cut your false positive rate in half with PlGF

ShapeShapeIntroducing the PlGF marker to the Combined test (NT, PAPP-A and free hCGB) delivers the same detection rate (DR) as that achieved with the combined test alone, but at a significantly lower false positive rate (FPR). In fact, the addition of PlGF at 11–13+6 weeks gives you two choices: You can reduce your FPR by 46% at a fixed DR or increase the overall DR by 3%.[3]



This Receiver Operating Characteristic curve that shows how the addition of PlGF (blue curve) lowers the risk cutoff level for 46% fewer false positives. The green curve shows performance for the combined test without PlGF, based on results reported by Pandya et al. (2012).

PlGF

Screen for Down Syndrome more effectively

Reduce cost and concern with PlGF

PlGF is the multipurpose biomarker of choice in prenatal screening. Not only does it reduce false positives, but also the need for invasive procedures. With PlGF in your screening program, you can achieve substantial cost savings and allocate resources where they are most needed. When PlGF is added to first trimester Down syndrome screening program, you can double the benefits by using the same result to calculate pre-eclampsia risk, as women with elevated pre-eclampsia risk show low levels of PlGF. The most effective way to identify women in high risk for pre-eclampsia is combined screening program with PlGF 1-2-3™ blood test, maternal medical history assessment, mean arterial blood pressure measurement and, if available, uterine artery Doppler ultrasonography.

Double the benefits

Revvity PlGF assay is CE-marked for both Down syndrome and pre-eclampsia screening. One assay, two risk results.

Expanded combined – optimum 1T performance with four markers

When even higher screening performance is needed, all four markers – PAPP-A, Free hCGß, AFP and PlGF – can be used together with ultrasound NT measurement to calculate the risk for aneuploidy.

The expanded combined model achieves a detection rate of more than 91% at a false positive rate of 5%, or a similar detection rate as with the combined model, but with 40% fewer false positives.[5]

1T QUAD for biochemistry only Down syndrome screening in first trimester

Comparison of first trimester screening models[5]

Model	Markers	DR (%) at FPR of 5%
1T Quad	PAPP-A + free hCGß + PlGF + AFP	81.7
1T Combined	PAPP-A + free hCGß + NT	87.2
1T Combined + PlGF	PAPP-A + free hCGß + NT + PlGF	89.8
1T Expanded combined	PAPP-A + free hCGß + NT + PlGF + AFP	91.2

NT= Nuchal Translucency, DR= Detection Rate, FPR= False Positive Rate

1T Quad – biochemistry only screening for first trimester

Revvity offers four CE-marked assays – PAPP-A, free hCGß, PlGF and AFP – for 1T screening of Down syndrome. Together these assays enable screening in the first trimester even in the absence of a NT measurement.

In fact, recent studies show that maternal serum placental growth factor (PlGF) and alpha fetoprotein (AFP) measured together with the two established markers PAPP-A and free hCGß in the first trimester of pregnancy can be more effective than conventional 2T triple marker tests.[5-8]

1T Quad is also similar in performance to the 2T Quad test.[5-8]

What is 1T Quad?

Four CE-marked assays – PAPP-A, free hCGß, PlGF and AFP together for 1T screening of Down syndrome.

Why choose 1T Quad?

- Biochemistry-only screening protocol for Down syndrome in the first trimester
- When NT measurement is not available –achieve performance equivalent to 2T screening
- Earlier risk assessment of other pregnancy complications like pre-eclampsia
- Cost-efficient management of screening resources

Support your NIPT program with contingent screening

Today non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) is available in many countries as an alternative method for the identification of chromosomal aneuploidies. Women who required invasive testing in the past now often choose NIPT as the first approach to confirm positive finding from serum screening. Although interest in NIPT is increasing rapidly, cost and availability continue to be a challenge.

Contingent screening is a cost-effective option if NIPT availability is limited. In contingent screening, pregnancies are classified into three risk groups using first trimester biochemistry and, if available, ultrasound results. Women with low risk pregnancies require no further testing for aneuploidy, while women with high risk pregnancies receive early prenatal diagnosis. Women in the intermediate group are referred to further testing.

Markers	DR%	FPR%
1T Quad (PAPP-A + free hCGß + PlGF + AFP)	98	38
1T Combined (NT + PAPP-A + free hCGß)	98	26
1T Quad + NT	98	17
1T Quad + NT + DV-PIV	98	8

DV-PIV = Ductus Venous Pulsatility Index
Modeled performance, Nicolaides et al.[9]

Where ultrasound resources are available, a significant reduction in the false positive rate is possible, thereby further reducing the percentage of women referred to NIPT.[9]

First trimester screening



Based on data by Nicolaides et al 2013.
* Tailored cutoffs can be implemented to optimize detection rates and the percentage of cfDNA testing required.

Contingent screening is also useful when access to ultrasound resources is limited. If ultrasound is not available to all, 1T Quad can be used as a first tier test to identify suitable women for ultrasound examination.

False Positive Rates at the Given Detection Rates[5]

Markers	90%	95%	98%
1T Combined (NT + PAPP-A + free hCGß)	4.3	11.2	25.5
1T Quad (PAPP-A free hCGß + PlGF + AFP)	13.1	23.1	38.0

Modeled performance, Nicolaides et al.[9]

For a 98% DR with 1T Quad, 38% of women would be referred to NT or NIPT. The higher false positive rate is acceptable because NT and NIPT are non-invasive techniques with minimal risk of fetal loss.[9]

Better care in the second trimester of pregnancy

Traditionally, screening for trisomies has been performed in the second trimester of pregnancy. Today, second trimester screening is often used in regions where ultrasound resources are not available for all or in case women don't contact their healthcare provider before the second trimester.

Second trimester markers are also important part of the integrated and sequential screening strategies, where the final risk is calculated based on both first and second trimester serum markers. Revvity supports all second trimester screening models, Double, Triple and Quad.

Second trimester screening models and detection rates at fixed 5% false positive rate

Screening model	Markers	DR*	FPR
2T Double	AFP + hCG or Free hCGß	65 – 70%	5%
2T Triple	AFP + hCG or Free hCGß + uE3	70 – 75%	5%
2T Quad	AFP + hCG or Free hCGß + uE3 + Inhibin A	72 – 83%	5%

*Given as examples, some variation depending on study

Inhibin A – upgrade to optimum 2T performance

Upgrading to the Quad test is often the only way to meet national screening guidelines for second trimester. Inhibin A is also used in integrated and serum integrated screening strategies.

When AutoDELFIA® Inhibin A is added to a combination of other 2T serum markers (AFP and free hCGß or AFP, free hCGß and uE3), the screening performance improves in both marker combinations.[10]

Performance of second trimester screening models with and without inhibin A.[10]

	Detection rate at 3% fixed False Positive Rate	Detection rate at 5% fixed False Positive Rate
free hCGß, AFP	62.8	65.1
free hCGß + AFP + Inhibin A	69.8	76.7
free hCGß, hAFP + uE3	62.8	67.4
free hCGß, hAFP + uE3 + Inhibin A	67.4	76.7

Excellent clinical performance

When compared to competitor's product, the results show excellent correlation between the two methods. In addition AutoDELFIA Inhibin A kit provides excellent precision over the whole clinically relevant concentration range, with total assay variation typically less than 5%. The Limit of Detection (LoD) was determined as 5,7 pg/ml based on 216 determinations of low level samples.[11]

Make sure you have all available options for second trimester screening and choose Revvity as your screening solution partner.



References

1. Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies. Ultrasound Obstet Gynecol. 2009 Apr; 33(4):382-6. doi: 10.1002/uog.6331.

2. Cowans NJ, Stamatopoulou A, Spencer K. First trimester maternal serum placental growth factor in trisomy 21 pregnancies. Prenat Diagn. 2010 May; 30(5):449-53. doi: 10.1002/pd.2496.

3. Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH. Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation. Fetal Diagn Ther. 2012;31(2): 87-93. doi: 10.1159/000335684. Epub 2012 Jan 27.

4. Wald NJ, Bestwick JP, George LM, Huttly WJ. Antenatal screening for Down syndrome using serum placental growth factor with the combined, quadruple, serum integrated and integrated tests. PLoS One. 2012;7(10):e46955. doi: 10.1371/journal.pone.0046955.

5. Huang T, Dennis A, Meschino WS, Rashid S, Mak-Tam E, Cuckle H. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-ß human chorionic gonadotrophin, placental growth factor, and ß-fetoprotein. Prenat Diagn. 2015 Jul;35(7):709-16. doi: 10.1002/pd.4597.

6. Rahim RR, Cuckle HS, Sehmi IK, Jones RG. Compromise ultrasound dating policy in maternal serum screening for Down syndrome. Prenat Diagn. 2002 Dec;22(13):1181-4.

7. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen. 2003;10(2):56-104. Erratum in: J Med Screen. 2006;13(1):51-2.

8. Harrison G, Goldie D. Second-trimester Down's syndrome serum screening: double, triple or quadruple marker testing?Ann Clin Biochem. 2006 Jan;43(Pt 1):67-72.

9. Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2013 Jul;42(1):41-50. doi: 10.1002/uog.12511. Epub 2013 Jun 7.

10. Wilson G, Liitti P, Pölönen T, Sairanen M, Spencer K. A technical and clinical evaluation of a new assay for inhibin A and its use in second trimester Down syndrome screening. Clin Chem Lab Med. 2016 Sep 1;54(9):1473-9. doi: 10.1515/cclm-2015-1118.

11. AutoDELFIA Inhibin A kit insert.

Revvity is committed to advancing maternal fetal health

With more than 10 million prenatal screens performed annually on our solutions, Revvity is the globally recognized leader in maternal fetal health. Our complete screening and diagnostic solutions, combining clinically proven assays, equipment and informatics, are devoted to supporting the needs of all women worldwide. Revvity is committed to leveraging this know ledge to advance the science of maternal fetal health and expand the capabilities of laboratory specialists and clinicians now, and in the future.



Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

www.revvity.com

Revvity, Inc.
940 Winter Street, Waltham, MA 02451 USA
(800) 762-4000 | www.revvity.com

For a complete listing of our global offices, visit www.revvity.com

1136033